top of page
Cancer patients have varied outcome after standard treatment regimen. The uncertainty of individual patient’s drug responses, even to targeted treatments prescribed patients based on their genomic and pathological profile, represents a significant unmet medical need.
Current needs
.png)
VivoZ BioLabs aims to establish a complimentary diagnosis device for personalized medicine based on our microFluidic Tissue Array (μFTA) technology. Oncologists can evaluate multiple clinical drugs simultaneously using cancer patient's biopsy tissues on our clinical μFTA platform. The drug showing the best efficacy can be chosen for therapeutic treatment of this patient.
Our goal
bottom of page